VIA
RXRX icon

Virtus Investment Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History

Virtus Investment Advisers’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$381K Buy
103,872
+40,897
+65% +$136K 0.09% 311
2026
Q1 		$193K Buy
62,975
+1,536
+3% +$5.94K 0.05% 377
2025
Q4 		$251K Buy
61,439
+39,430
+179% +$195K 0.07% 328
2025
Q3 		$107K Buy
22,009
+3,821
+21% +$20.1K 0.03% 419
2025
Q2 		$92K Sell
18,188
-5,330
-23% -$26.2K 0.03% 368
2025
Q1 		$124K Buy
+23,518
New +$171K 0.03% 386

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Virtus Investment Advisers's RXRX Position: Q2 2026 in Review

Virtus Investment Advisers increased its Recursion Pharmaceuticals (RXRX) stake by 65% in Q2 2026, buying an estimated $136K and bringing the position to 103,872 shares worth $381K. The position accounts for 0.09% of the portfolio, ranked #311.

Virtus Investment Advisers first reported a position in RXRX in Q1 2025 and has held it in 6 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Virtus Investment Advisers held 103,872 shares of Recursion Pharmaceuticals worth $381K as of Q2 2026.
  • Virtus Investment Advisers bought 40,897 Recursion Pharmaceuticals shares in Q2 2026, an estimated $136K.
  • Recursion Pharmaceuticals made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #311 holding.
  • Virtus Investment Advisers first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.